[Therapeutic efficiency of an angiogenesis inhibitor, TNP-470, against carcinomatous peritonitis in rodents]

K Ozaki; T Takahashi; A Hagiwara; M Shimotsuma; C Sakakura; S Sasaki; M Shirasu; H Tsujimoto; T Oyama; T Sakakibara

[Therapeutic efficiency of an angiogenesis inhibitor, TNP-470, against carcinomatous peritonitis in rodents]

Gan To Kagaku Ryoho. 1993 Aug;20(11):1575-7.

[Article in Japanese]

Authors

K Ozaki¹, T Takahashi, A Hagiwara, M Shimotsuma, C Sakakura, S Sasaki, M Shirasu, H Tsujimoto, T Oyama, T Sakakibara, et al.

Affiliation

¹ First Dept. of Surgery, Kyoto Prefectural University of Medicine.

PMID: 8373222

Abstract

TNP-470, an analog of fumagillin, is one of the new angiogenesis inhibitors. Five days after an intraperitoneal inoculation of 10(7) cells of Walker 256 carcinosarcoma to SD rats, TNP-470 was injected intraperitoneally in the form of TNP aqueous solution or TNP-oil solution. Mean survival time of rats given TNP-oil solution or TNP aqueous solution was statistically prolonged, compared with that of the control rats. Our results showed that TNP-470 is an effective therapeutic drug for carcinomatous peritonitis.

MeSH terms

Animals
Antibiotics, Antineoplastic / therapeutic use*
Carcinoma 256, Walker / complications*
Cyclohexanes
Infusions, Parenteral
Male
Melanoma, Experimental / complications*
Mice
Mice, Inbred C57BL
O-(Chloroacetylcarbamoyl)fumagillol
Peritonitis / drug therapy*
Peritonitis / etiology
Rats
Sesquiterpenes / therapeutic use*

Substances

Antibiotics, Antineoplastic
Cyclohexanes
Sesquiterpenes
O-(Chloroacetylcarbamoyl)fumagillol